2020
DOI: 10.1101/2020.06.23.167668
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Elevated somatic mutation burdens in normal human cells due to defective DNA polymerases

Abstract: Mutation accumulation over time in normal somatic cells contributes to cancer development and is proposed as a cause of ageing. DNA polymerases Pol e and Pol d replicate DNA with high fidelity during normal cell divisions. However, in some cancers defective proofreading due to acquired mutations in the exonuclease domains of POLE or POLD1 causes markedly elevated somatic mutation burdens with distinctive mutational signatures. POLE and POLD1 exonuclease domain mutations also cause familial cancer predispositio… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
5
4

Relationship

4
5

Authors

Journals

citations
Cited by 14 publications
(17 citation statements)
references
References 66 publications
(133 reference statements)
0
17
0
Order By: Relevance
“…From this set of observations, we quantified the overdispersion parameter (rho). Any variant with an estimated rho smaller than 0.1 was filtered out, as used previously 39,40 .…”
Section: Unmatched Substitution Callingmentioning
confidence: 99%
“…From this set of observations, we quantified the overdispersion parameter (rho). Any variant with an estimated rho smaller than 0.1 was filtered out, as used previously 39,40 .…”
Section: Unmatched Substitution Callingmentioning
confidence: 99%
“…We called single nucleotide variants (SNVs) against the human reference genome. Germline and artefactual variants were filtered out using an exact binomial test and a test for beta-binomial over-dispersion 8,1618 ( Methods ).…”
Section: Resultsmentioning
confidence: 99%
“…Interestingly, their mutations will thus only appear in cells that are not quiescent when the nucleotide pool is altered 29–31,44,45 . This explains why 5-FU mutations do not appear in treatment-related AMLs, and only in some healthy colonic crypts of patients exposed to 5-FU or capecitabine 46 .…”
Section: Discussionmentioning
confidence: 99%